Compare Agilent Technologies Inc (A) vs Brunswick Corporation (BC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Brunswick Corporation — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Brunswick Corporation trades at $81.32 (market cap $5.21B). The key difference: Agilent Technologies Inc is far larger — about 8.1× Brunswick Corporation's market cap, and Brunswick Corporation pays the higher dividend (2.19%). Which is the better fit depends on your goals.
| A | BC | |
|---|---|---|
Market Cap | $42.00B | $5.21B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $89.22 |
52-Week Low | $110.24 | $56.70 |
Enterprise Value | $43.55B | $7.21B |
Dividend Yield | 0.69% | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
BC trades at $81.55, up 0.37% with a bullish technical signal. Recent Q2 2026 earnings beat estimates with EPS of $1.56 versus $1.19 expected. The company maintains a dividend of $0.44 per share and has strong analyst support with 22 buy ratings. However, negative net income margin and ROE highlight profitability challenges amid declining revenue trends from $6.8B in 2022 to $5.4B in 2025.
Outlook is cautiously optimistic due to earnings beats and institutional buying, but high P/E of 73.92 and persistent net losses pose valuation and execution risks. The consensus price target of $85.33 suggests modest upside, contingent on reversing profit declines and stabilizing cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →
